Delivery Order SPE2DE24D0013-SPE2D626F627F
- Not listed
- This delivery order, valued at $19,375.00, was awarded to Cepheid Inc. on December 8, 2025, by the Defense Logistics Agency Medical Supply Chain, with ultimate completion scheduled for December 15, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, issued under the XPRS4PLEX-10 procurement vehicle. Cepheid, headquartered in Sunnyvale, California, is a leading manufacturer of advanced molecular diagnostic systems and reagents specializing in rapid infectious...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, was awarded a delivery order valued at $2,720 on October 29, 2025, by the Defense Logistics Agency Medical Supply Chain for diagnostic testing supplies and reagents. The delivery order, designated as XPRS4PLEX-10, is structured as a firm fixed-price contract with an ultimate completion date of November 5, 2025, and no set-aside designation. This award falls under Cepheid's broader contracting...
- This delivery order, valued at $34,225.20, was awarded on December 8, 2025, by the Defense Logistics Agency's Medical Supply Chain to Cepheid Inc. for molecular diagnostic testing supplies related to COVID-19, influenza, and respiratory syncytial virus detection. The contract carries a firm fixed-price structure with no set-aside designation and is scheduled for completion by December 15, 2025. Cepheid, headquartered in Sunnyvale, California, is a leading federal supplier of advanced molecular...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, was awarded a delivery order valued at $27,650.40 by the Defense Logistics Agency Medical Supply Chain on November 13, 2025. This firm fixed-price delivery order, designated XPRSMVP-10 with completion targeted for November 20, 2025, represents a procurement of diagnostic testing supplies and reagents under an existing indefinite delivery contract vehicle. The award carries no set-aside designation,...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, was awarded a delivery order valued at $10,200.00 by the Defense Logistics Agency Medical Supply Chain on December 10, 2025. The firm fixed-price delivery order, with an ultimate completion date of December 17, 2025, is designated as XPRS4PLEX-10 and carries no set-aside designation. This delivery order falls under Cepheid's broader contracting relationship with federal healthcare agencies, where...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems and reagents, was awarded a delivery order valued at $5,236.00 by the Defense Logistics Agency Medical Supply Chain on October 27, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, is for diagnostic testing supplies supporting detection of COVID-19, influenza, and respiratory syncytial virus, with a firm fixed-price structure and ultimate completion date of November 10, 2025. The contract...
- Cepheid Inc., a molecular diagnostics manufacturer headquartered in Sunnyvale, California, was awarded a delivery order valued at $5,440 on December 5, 2025, by the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order, designated as XPCOV2/FLU/RSV-10, is scheduled for completion by December 12, 2025, and will be performed at the contractor's Sunnyvale facility. The award carries no set-aside designation, reflecting Cepheid's competitive positioning in...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a firm fixed-price delivery order valued at $1,968.80 by the Defense Logistics Agency's Medical Supply Chain on April 23, 2025, with an ultimate completion date of May 7, 2025. This delivery order, which carries no set-aside designation, represents a continuation of Cepheid's ongoing provision of diagnostic equipment and testing solutions to federal healthcare systems. The contract is likely...
- This delivery order, valued at $1,235.85, was awarded to Cepheid Inc. on November 25, 2025, by the Defense Logistics Agency Medical Supply Chain for diagnostic supplies supporting federal healthcare operations. The order, designated as XPRSARS-COV2-10, is structured as a firm fixed-price delivery order with no set-aside designation and is scheduled for completion by December 10, 2025. Performance will be executed at Cepheid's headquarters facility in Sunnyvale, California. This award...
- The Defense Logistics Agency (DLA), under the Medical Supply Chain program, awarded a delivery order valued at $1,648.38 to Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, on August 12, 2025. This firm fixed-price delivery order, without set-aside designation, represents a continuation of Cepheid's ongoing provision of diagnostic testing solutions to federal defense and healthcare agencies. The contract is scheduled for ultimate completion by August 19, 2025,...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D626F627FDelivery Order
This delivery order, valued at $12,780, was awarded to Cepheid Inc. on December 2, 2025, by the Defense Logistics Agency Medical Supply Chain, a defense-focused federal agency. The contract represents a firm fixed-price delivery order with no set-aside designation for diagnostic testing supplies and reagents, with an ultimate completion date of December 9, 2025. Cepheid, headquartered in Sunnyvale, California, is a leading manufacturer of molecular diagnostic systems, particularly its GeneXpert diagnostic platform, which serves as a critical testing solution across multiple federal healthcare agencies including the Department of Veterans Affairs, Indian Health Service, Defense Health Agency, and the U.S. Coast Guard. This award falls under Cepheid's broader federal contracting portfolio, which includes substantial Indefinite Delivery Contracts with the VA's Veterans Integrated Service Networks, including a $6.7 million contract with VISN 17 and a $32.8 million contract with VISN 6 extending through 2029-2030. The company has established itself as a primary federal supplier of diagnostic testing solutions for infectious diseases, including COVID-19, influenza, respiratory syncytial virus, tuberculosis, and other conditions. The company's extensive track record in firm fixed-price contracting across federal healthcare procurement demonstrates its competitive positioning and capability to deliver molecular diagnostic testing supplies and services to support clinical laboratory operations throughout the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 12/1/25 |